Lucía Notario

Aware Oncologist👩🏼‍⚕️📚#GastrointestinalTumors 📍Hospital de Granollers, Vallès Oriental #AlwaysLearning 🔬🩺

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 ASCO2026 | HERIZON-GEA-01

zanidatamab + tislelizumab + CT vs trastuzumab + CT in HER2+ mGEA

📈 PFS: 12.4 vs 8.1 mo
• HR 0.63

📈 OS: 26.4 vs 19.2 mo
• HR 0.72

🎯 Benefit irrespective of PD-L1 status

⚠️ Manageable safety profile; diarrhea was the most common grade ≥3 AE.
@OncoAlert

[Arndt Vogel @ArndtVogel]

BREAKWATER: PFS and OS analyses of 1L encorafenib + cetuximab + FOLFIRI in BRAF V600E-mCRC
#ASCO26
👉mPFS 8.3 vs 15.2 mo
👉mOS NE vs 20 mo
🧐significant benefit, valid alternative, approved by FDA...
@myesmo @ASCO

[Arndt Vogel @ArndtVogel]

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial.
#ASCO26
👉exercise improves DFS and OS
👉Despite upfront costs, overall cost effective
🧐provides economic evidence for clinical implantation
@myesmo @ASCO

[Arndt Vogel @ArndtVogel]

Adjuvant aspirin for stage III CRC after curative resection: Primary analysis of the double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C)
#ASCO26
👉well tolerated, but no significant benefit in unselected pts in stage III
👉biomarker analysis ongoing
@myesmo @ASCO

[Arndt Vogel @ArndtVogel]

👏Standing ovations for Daraxonrasib👏
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic cancer: Primary and final analysis from the phase-3 RASolute 302 study
👉mPFS 7.6 vs 3.5 mo
👉mOS: 13.2 vs 6.6 mo
👏Fantastic news, new standard of care
@myesmo @ASCO

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Institut Català d'Oncologia @ICO_oncologia]

L’oncòloga mèdica d’@ICO_oncologia Badalona i investigadora @GTRecerca, @MariaSaigi, rep la beca @Icapem_vida 2025 per estudiar la relació entre fibrosi pulmonar i #càncer de pulmó.
Una recerca amb mirada de gènere per avançar en el diagnòstic precoç i la medicina de precisió.

[Eduardo Terán @EduardoTB94]

🔎 Check out our review 🙇🏼
Terrific team work “Evolving treatment strategies for resectable gastric cancer: Bridging Asia–West disparities toward personalized and integrated therapy”
https://t.co/fvbzQcIOun
…New projects on the horizon 🌄

[Arndt Vogel @ArndtVogel]

MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma
#ESMO25 #ESMOAmbassadors
👉 pCR: 16%, MPR: 26%, any: 87%
👉 OS: HR: 0.78; 36-mo OS: 68 vs 61%
🧐OS improved independent of TAP, better in responders > new SOC
@myesmo

[ACTEG @ACTEG_]

📢 El 9 d’octubre al Hospital de Granollers
State-of-the-Art Management of Localized Esophagogastric Tumors
🔹 Taules rodones interactives
🔹 Highlights científics
🔹 Debat multidisciplinari
🕠 17:30-20:00h
📩 Inscripcions: [email protected]
@HelenaVerdaguer

[Mario Balsa @MarioBalsaMD]

🚨 Who should undergo pancreatic cancer screening? 🤔 #ESMOGI25

▪️PRSS1 (Hereditary Pancreatitis): RR ~53–87, risk up to 55%
▪️STK11 (Peutz-Jeghers): RR ~132, lifetime risk 11–36%
▪️CDKN2A (FAMMM): RR ~20–40, risk up to 25%
▪️SPINK1, TP53, BRCA1/2, PALB2, ATM, Lynch, FPC: All carry elevated risk!

The pancreas doesn’t forget—especially when your DNA does the talking 🧬

#OncoAlertAF @OncoAlert

@myESMO @_SEOM @GrupoTTD

[Arndt Vogel @ArndtVogel]

NIVO + IPI vs NIVO for MSI-H/dMMR mCRC: Health-related quality of life analysis
🔎CheckMate 8HW
👉mPFS clearly improved
👉 HRQoL, less symptoms
🧐 Supports use of Nivo IPI as 1st line treatment in MSI CRC
#ESMOAmbassadors #ESMOGI25 @myESMO

[ACTEG @ACTEG_]

🚨 DESTINY-Gastric04: T-DXd significantly improves survival in advanced HER2+ gastric/GEJ cancer.
👉OS 14.7 vs. 11.4 m (HR 0.70, p=0.004)
👉PFS: 6.7 vs 5.6 m
👉ORR: 44.3% vs 29.1%
😣ILD/pneumonitis un 13.9%
📈 New global standard of care established.

[NEJM @NEJM]

Presented at #ASCO25:

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial results: https://t.co/IM8wwyIAad

[Arndt Vogel @ArndtVogel]

Durvalumab + FLOT in resectable GC/GEJ cancer
#ASCO25 Plenary session
🔎MATTERHORN
👉mEFS n.r. vs 32.8, HR 0.71
👉mDFS n.r. vs 39.8 mo
👉OS n.r. in both arms, HR 0.78, not (yet) significant
👉pCR 19 vs 7%
🧐 Finally, ICI arrived in the peri-operative setting
@myESMO

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔴 Añadir terapia de campos eléctricos mejora la supervivencia y el control del dolor en pacientes con cáncer de páncreas localmente avanzado. 

El estudio, liderado por @MacarullaTeresa, se presenta hoy en #ASCO25 y se publica en @JCO_ASCO.

👉 https://t.co/L4jDPEQAso

[Lucía Notario @DrNotarioR]

🙌🏻🙌🏻 today @AstraZeneca

[Dr Amol Akhade @SuyogCancer]

Top 10 GI Trials – ASCO 2025
The biggest GI breakthroughs you must track this year!

🧬 ATOMIC – Atezolizumab + FOLFOX in stage III MSI-H colon

🛡️ MATTERHORN – Durvalumab + FLOT in gastric/GEJ

🧪 DYNAMIC-III – ctDNA-guided chemo in colon

💉 DESTINY-Gastric04 – T-DXd vs RAM+PTX in HER2+ GEJ

🥊 LBA4004 – mFOLFIRINOX vs PAXG in resectable PDAC

🔄 BREAKWATER (Updated) – Encorafenib + Cetuximab in BRAF mCRC

⚔️ ANCHOR – Anlotinib vs Bevacizumab in RAS/BRAF WT mCRC

✅ CheckMate 577 (Updated) – Adjuvant nivo in EC/GEJ

🔬 Actuate 1801 – Elraglusib + nab-Gem in PDAC

🧯 POLCAGB – Chemo vs CRT in gallbladder cancer
Do check out the Data at @ASCO
#ASCO25 #GIonc #Oncology @OncBrothers @OncoAlert

[Hospital Universitari Bellvitge | HUB @hbellvitge]

L’#hbellvitge porta a terme per 1️⃣a vegada a Espanya una tècnica quirúrgica per extirpar càncers de pàncrees fins ara inoperables.

🔹Aquesta cirurgia permet operar tumors complexos amb important afectació venosa mitjançant una tècnica de derivació provisional del reg sanguini.

🔹 La intervenció ha estat possible gràcies a l’elaboració prèvia d’un model en tres dimensions de planificació quirúrgica avançada.

ℹ️ https://t.co/RzUMMK2OlB
#InnovacióHUB #orgullbellvitge #SocialmentResponsables #EquipHUB

[ASEICA @ASEICAnews]

📍España tarda de media 721 días en aprobar fármacos oncológicos tras el okey de la @EMA_News⏱

¿Cuántas vidas cuestan estos retrasos? Pedimos acceso a la innovación oncológica➕ágil y equitativo

Accede a la info. completa elaborada por ASEICA: https://t.co/xn36vTLBTU